One Hour Preoperative Gatifloxacin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00350363
Recruitment Status : Completed
First Posted : July 10, 2006
Results First Posted : January 29, 2015
Last Update Posted : January 29, 2015
Information provided by (Responsible Party):
Christopher Ta, Stanford University

Brief Summary:
Comparison of 1 day versus 1 hour application of topical Zymar.

Condition or disease Intervention/treatment Phase
Ophthalmic Surgery Drug: Zymar Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Prevention
Official Title: One Hour Preoperative Gatifloxacin
Study Start Date : January 2007
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1 hour gatifloxacin
presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
Drug: Zymar
zymar qid
Other Name: gatifloxacin

Primary Outcome Measures :
  1. Number of Participant With Positive Culture [ Time Frame: 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ophthalmic surgery

Exclusion Criteria:

  • taken antibiotics, allergic to fluoroquinolones

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00350363

United States, California
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Principal Investigator: Christopher Ta, MD Stanford University

Responsible Party: Christopher Ta, PI, Stanford University Identifier: NCT00350363     History of Changes
Other Study ID Numbers: 5004
First Posted: July 10, 2006    Key Record Dates
Results First Posted: January 29, 2015
Last Update Posted: January 29, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Nucleic Acid Synthesis Inhibitors